Cancer has been declared as one of the leading causes of death by the World Health Organization (WHO). The global economic burden of cancer is undeniable with projections estimating nearly $25 trillion in the year 2050. In the United States alone ~600K deaths have been estimated in 2023. In this bleak landscape, immuno-oncology -a field at the forefront of cancer research and treatment, has emerged as a beacon of hope in the fight against various types of cancers. Harnessing the body's immune system to recognize, target, and eliminate tumor cells, immuno-oncology's extraordinary promise and rapid growth have captured the attention of researchers and pharmaceutical industries worldwide. This burgeoning potential and heightened interest are vividly reflected in the growing number of scientific publications (Fig. ), especially in the last four years, and the escalating number of drugs under evaluation in clinical trials since 2015 (Fig. ) accounting for ~5,500 clinical trials currently ongoing across various clinical phases.